Golimumab
- Generic Name
- Golimumab
- Brand Names
- Simponi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 476181-74-5
- Unique Ingredient Identifier
- 91X1KLU43E
- Background
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to se...
- Indication
Used in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) in patients 2 years old and above with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS) or in combination with methotrexate, and (iv) as a single agent in patients w...
- Associated Conditions
- Active Polyarticular Juvenile Idiopathic Arthritis (pJIA), Severe Ulcerative Colitis, Active Ankylosing spondylitis, Active Psoriatic arthritis, Moderate Ulcerative colitis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 34
- Registration Number
- NCT05960578
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 150
- Registration Number
- NCT05669833
- Locations
- 🇺🇸
Family Arthritis Center, Loxahatchee Groves, Florida, United States
🇺🇸Healing Rheumatology, Plant City, Florida, United States
🇺🇸Southwest Florida Rheumatology, Riverview, Florida, United States
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
- Conditions
- Interventions
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 703
- Registration Number
- NCT05242471
- Locations
- 🇺🇸
Moore Clinical Trials, LLC, Little Rock, Arkansas, United States
🇺🇸Om Research LLC, Apple Valley, California, United States
🇺🇸Valley Gastroenterology Medical Group, Arcadia, California, United States
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 577
- Registration Number
- NCT05242484
- Locations
- 🇯🇵
University Hospital Kyoto Prefectural University of Medicine, Kyoto, Japan
🇯🇵Kyoto University Hospital, Kyoto, Japan
🇯🇵Gunma University Hospital, Maebashi, Japan
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2021-10-08
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 91
- Registration Number
- NCT05071664
- Locations
- 🇺🇸
Great Lakes Center of Rheumatology, Lansing, Michigan, United States
🇺🇸Clinvest, Springfield, Missouri, United States
🇺🇸Jacobi Medical Center, Bronx, New York, United States
Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D
CHronic Nonbacterial Osteomyelitis International Registry
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT04725422
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 270
- Registration Number
- NCT04610476
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Medical University of Graz
- Target Recruit Count
- 10
- Registration Number
- NCT04200833
Effectiveness and Adherence of Golimumab in Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04188249
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.